Filing Details
- Accession Number:
- 0000950170-23-009170
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-22 16:06:50
- Reporting Period:
- 2023-03-20
- Accepted Time:
- 2023-03-22 16:06:50
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
31791 | Perkinelmer Inc | PKI | Laboratory Analytical Instruments (3826) | 042052042 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1665985 | R Daniel Tereau | 940 Winter Street Waltham MA 02451 | Please See Remarks | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-03-20 | 3,750 | $52.65 | 22,352 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-03-20 | 15 | $121.69 | 22,337 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-03-20 | 5,122 | $123.37 | 17,215 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-03-20 | 5,304 | $124.01 | 11,911 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-03-20 | 300 | $124.79 | 11,611 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | NQ Stock Option (right to buy) | Disposition | 2023-03-20 | 3,750 | $0.00 | 3,750 | $52.65 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2024-02-07 | No | 4 | M | Direct |
Footnotes
- The Exercise Price included on the Form 4 filed on February 8, 2017 for the Reporting Person was incorrectly reported due to administrative error.
- The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Tereau on February 16, 2023.
- The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $121.66 to $121.74. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $122.74 to $123.72. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $123.74 to $124.73. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $124.74 to $124.81. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- This option became exercisable in three equal annual installments beginning on February 7, 2018, which was the first anniversary of the date on which the option was granted.